Treatment Outcomes of Durvalumab Combination Therapy in Patients with Biliary Tract Cancer.

Q3 Medicine

Tokai Journal of Experimental and Clinical Medicine Pub Date : 2026-04-20

Hiroyuki Ito, Seiichiro Kojima, Yousuke Tazawa, Yuji Omura, Toru Yamaguchi, Tsubomi Cho, Shihou Yoshihara, Junko Nagata, Shunji Hirose, Toshihito Ogasawara, Hideki Izumi, Junichi Kaneko, Takayoshi Suzuki

引用次数: 0

Abstract

Objectives: This study aimed to evaluate the efficacy and safety of gemcitabine, cisplatin, and durvalumab (GCD) combination therapy in patients with biliary tract cancer treated at our hospital.

Methods: Nineteen patients diagnosed with biliary tract cancer and treated with durvalumab combination therapy at Tokai University Hachioji Hospital between February 1, 2023, and May 31, 2024, were included in this retrospective study.

Results: The median overall survival was 13.7 months, and the median progression-free survival was 7.3 months, comparable to outcomes reported in the TOPAZ-1 trial.

Conclusion: GCD therapy demonstrated efficacy and safety similar to those observed in the TOPAZ-1 trial.

本刊更多论文

Durvalumab联合治疗胆道癌患者的治疗结果。

目的：本研究旨在评价吉西他滨、顺铂和杜伐单抗（GCD）联合治疗在我院治疗的胆道肿瘤患者的疗效和安全性。方法：回顾性研究于2023年2月1日至2024年5月31日在东海大学八路医院诊断为胆道癌并接受durvalumab联合治疗的19例患者。结果：中位总生存期为13.7个月，中位无进展生存期为7.3个月，与TOPAZ-1试验报告的结果相当。结论：GCD治疗的疗效和安全性与TOPAZ-1试验相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tokai Journal of Experimental and Clinical Medicine Medicine-Medicine (all)

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.